Jazz Pharmaceuticals
JAZZ
#2324
Rank
$6.56 B
Marketcap
$106.59
Share price
3.58%
Change (1 day)
-4.84%
Change (1 year)

P/E ratio for Jazz Pharmaceuticals (JAZZ)

P/E ratio as of May 2025 (TTM): 14.3

According to Jazz Pharmaceuticals's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 14.3074. At the end of 2023 the company had a P/E ratio of 18.8.

P/E ratio history for Jazz Pharmaceuticals from 2007 to 2024

PE ratio at the end of each year

Year P/E ratio Change
202318.8-141.73%
2022-45.090.04%
2021-23.7-161.84%
202038.3136.52%
201916.2-2.56%
201816.60.33%
201716.6-0.2%
201616.6-36.48%
201526.1-85.16%
2014176

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
-0.0001-100.00%๐Ÿ‡ฎ๐Ÿ‡ช Ireland
21.7 51.74%๐Ÿ‡บ๐Ÿ‡ธ USA
17.8 24.17%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
-19.9-238.88%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.